Difference between revisions of "Afuresertib (GSK-2110183)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== Oral AKT inhibitor ==Preliminary results== # Spencer A, Yoon SS, Harrison SJ, Morris SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB, Chen ...") |
m |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | Oral | + | Oral AKT1 inhibitor |
==Preliminary results== | ==Preliminary results== | ||
| Line 7: | Line 7: | ||
[[Category:Investigational]] | [[Category:Investigational]] | ||
| − | [[Category: | + | [[Category:AKT1 inhibitors]] |
Revision as of 21:54, 6 October 2014
Mechanism of action
Oral AKT1 inhibitor
Preliminary results
- Spencer A, Yoon SS, Harrison SJ, Morris SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB, Chen C. The novel AKT inhibitor afuresertib shows
favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5. Epub 2014 Jul 29. link to original article PubMed